Cancer Colon

Vera, Robyn B.; Arthur, Douglas W.; Wazer, David E.; Lanciano, Rachelle; Brashears, James H.; Rengan, Ramesh; Thomas, Charles R.; Donahue, Bernadine R.; Cooper, Jay S.; Guerrieri, Patrizia; Montemaggi, Paolo; Oliai, Caspian; Pérez, Carlos A.; Thorstad, Wade L.; Michalski, Darek; Huq, M. Saiful; Knowlton, Christin A.; Mackay, Michelle Kolton; Limbergen, Erik; Choo, Bok Ai; Lu, Jiade J.; Brady, Luther W.; Yeung, Daniel; Palta, Jatinder; Huth, Bradley J.; Reiff, Jay E.; Yaeger, Theodore E.; Dragun, Anthony E.; Nieder, Carsten; Troicki, Filip T.; Poli, Jaganmohan; Budach, Volker; Gracely, Edward J.; Scanderbeg, Daniel J.; Christodouleas, John P.; Holmes, Timothy; Fisher, Brandon J.; Daugherty, Larry C.; Speer, Tod W.; Claßen, Johannes; Mose, Stephan; Heese, Curt; Laramore, George E.; Liao, Jay J.; Rockhill, Jason K.; Rübe, Claudia E.

doi:10.1007/978-3-540-85516-3_1047

Cited by 6 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(iii) Colonoscopy can directly visualize the shape, size, and position of the tumor in addition to the ability to obtain a biopsy from the suspected lesion. Colonoscopy has a very high sensitivity, up to 94.7%, but it may miss lesions mainly in the right side of the colon ( 35 ). (iv) Following a barium enema, an X-ray examination may detect evidence of mucosal damage and filling defects at the tumor site.…”

Section: Discussionmentioning

confidence: 99%

The Role of Tumor Parenchymal and Stromal Ratios in Colorectal Cancer

Imanbayev,

Iztleuov,

Koishybaev

et al. 2024

JFRH

View full text Add to dashboard Cite

Objective: To evaluate the implications and significant role of parenchymal and stromal ratio in colorectal cancer (CRC). Materials and methods: In our review, we involved English studies from common databases such as Web of Science, Scopus, Google Scholar, PubMed, and the Cochrane Library using the following keywords “colorectal cancer”, “tumor stromal ratio”, “tumor parenchymal ratio”, and “prognostic marker” till December 2023. Results: The majority of CRC patients are usually diagnosed at late stages, which may lead to missing out on the chance to get radical therapy. Patients with unfavorable prognosis have epithelial malignant tumors with a high amount of stroma, more than 50% stroma, while tumors with a low amount of stroma, less than 50%, and abundant carcinoma tissue have a better prognosis. Conclusion: Tumor-stromal ratio is a valuable, cheap, and fast modality that provides valuable prognostic data of colorectal carcinoma and other cancers.

show abstract

Section: Discussionmentioning

confidence: 99%

The Role of Tumor Parenchymal and Stromal Ratios in Colorectal Cancer

Imanbayev,

Iztleuov,

Koishybaev

et al. 2024

JFRH

View full text Add to dashboard Cite

show abstract

“…Whereas people having adenomatous polyps or polyps with villous or tubulovillous dysplasia are at higher risk of developing synchronous and metachronous CRC primary cancer. Unfortunately, people who survived cancer at a childhood age and received abdominal radiation are at higher risk of developing CRC thus, it is recommended to adopt a screening session after 10 years or at the age of 35 ( 3 ). Hence, the early detection and removal of preformed or developing polyps will eliminate the chances of CRC.…”

Section: Introductionmentioning

confidence: 99%

Non-steroidal anti-inflammatory drugs and biomarkers: A new paradigm in colorectal cancer

Rashid

Khan²,

Elsori³

et al. 2023

Front. Med.

View full text Add to dashboard Cite

Colorectal cancer is a sporadic, hereditary, or familial based disease in its origin, caused due to diverse set of mutations in large intestinal epithelial cells. Colorectal cancer (CRC) is a common and deadly disease that accounts for the 4th worldwide highly variable malignancy. For the early detection of CRC, the most common predictive biomarker found endogenously are KRAS and ctDNA/cfDNA along with SEPT9 methylated DNA. Early detection and screening for CRC are necessary and multiple methods can be employed to screen and perform early diagnosis of CRC. Colonoscopy, an invasive method is most prevalent for diagnosing CRC or confirming the positive result as compared to other screening methods whereas several non-invasive techniques such as molecular analysis of breath, urine, blood, and stool can also be performed for early detection. Interestingly, widely used medicines known as non-steroidal anti-inflammatory drugs (NSAIDs) to reduce pain and inflammation have reported chemopreventive impact on gastrointestinal malignancies, especially CRC in several epidemiological and preclinical types of research. NSAID acts by inhibiting two cyclooxygenase enzymes, thereby preventing the synthesis of prostaglandins (PGs) and causing NSAID-induced apoptosis and growth inhibition in CRC cells. This review paper majorly focuses on the diversity of natural and synthetic biomarkers and various techniques for the early detection of CRC. An approach toward current advancement in CRC detection techniques and the role of NSAIDs in CRC chemoprevention has been explored systematically. Several prominent governing mechanisms of the anti-cancer effects of NSAIDs and their synergistic effect with statins for an effective chemopreventive measure have also been discussed in this review paper.

show abstract

“…However, most drugs and their combinations generate side effects that can lead to treatment failure. For example, neurotoxicity is induced by OXA [ 7 ], cardiotoxicity by 5-fluorouracil [ 8 ], and severe neutropenia and hypersensitivity reactions follow paclitaxel treatment [ 9 ]. Additionally, drug resistance mechanisms induced by cytotoxins lead to poor response to chemotherapy and patient relapse [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Nanomedicine and Hyperthermia for the Treatment of Gastrointestinal Cancer: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

The incidence of gastrointestinal cancers has increased in recent years. Current treatments present numerous challenges, including drug resistance, non-specificity, and severe side effects, needing the exploration of new therapeutic strategies. One promising avenue is the use of magnetic nanoparticles, which have gained considerable interest due to their ability to generate heat in tumor regions upon the application of an external alternating magnetic field, a process known as hyperthermia. This review conducted a systematic search of in vitro and in vivo studies published in the last decade that employ hyperthermia therapy mediated by magnetic nanoparticles for treating gastrointestinal cancers. After applying various inclusion and exclusion criteria (studies in the last 10 years where hyperthermia using alternative magnetic field is applied), a total of 40 articles were analyzed. The results revealed that iron oxide is the preferred material for magnetism generation in the nanoparticles, and colorectal cancer is the most studied gastrointestinal cancer. Interestingly, novel therapies employing nanoparticles loaded with chemotherapeutic drugs in combination with magnetic hyperthermia demonstrated an excellent antitumor effect. In conclusion, hyperthermia treatments mediated by magnetic nanoparticles appear to be an effective approach for the treatment of gastrointestinal cancers, offering advantages over traditional therapies.

show abstract

Cancer Colon

Cited by 6 publications

References 0 publications

The Role of Tumor Parenchymal and Stromal Ratios in Colorectal Cancer

The Role of Tumor Parenchymal and Stromal Ratios in Colorectal Cancer

Non-steroidal anti-inflammatory drugs and biomarkers: A new paradigm in colorectal cancer

Nanomedicine and Hyperthermia for the Treatment of Gastrointestinal Cancer: A Systematic Review

Contact Info

Product

Resources

About